PRECISION BIOSCIENCES INC DTIL
We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")). We believe that the ARCUS platform's key capabilities and differentiating characteristics can be leveraged for effective and safe therapeutic outcomes.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34.3M | $68.7M | $48.7M | $25.1M | $115.5M | $24.3M | $22.2M | $10.9M | — |
| R&D | $54.2M | $59.6M | $53.4M | $46.1M | $115.2M | $98.1M | $82.4M | $45.1M | — |
| SG&A | $32.2M | $35.3M | $39.1M | $41.3M | $39.7M | $36.1M | $27.0M | $13.7M | — |
| Total operating expenses | $86.4M | $94.9M | $92.5M | $87.4M | $154.9M | $134.1M | $109.4M | $58.8M | — |
| Operating income | -$52.1M | -$26.2M | -$43.7M | -$62.3M | -$39.4M | -$109.8M | -$87.2M | -$47.9M | — |
| Interest expense | $1.4M | $1.8M | $2.2M | $1.1M | $132.0K | — | $182.0K | — | — |
| Pre-tax income | -$45.7M | $7.2M | — | — | — | -$109.0M | — | — | — |
| Income tax | $0 | $0 | — | — | — | $23.0K | — | — | — |
| Net income | -$45.7M | $7.2M | -$61.3M | -$111.6M | -$30.6M | -$109.0M | -$92.9M | -$46.0M | — |
| EPS, basic | -3.56 | 1.05 | -15.96 | -38.10 | -0.52 | — | — | — | — |
| EPS, diluted | -3.56 | 1.04 | -15.96 | -38.10 | -0.52 | -2.09 | -2.21 | -2.92 | — |
| Shares, diluted (wtd. avg.) | 12.8M | 6.9M | 3.8M | 2.9M | 58.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $110.8M | $85.9M | $116.7M | $189.6M | $143.7M | $89.8M | $180.9M | $103.2M | $62.8M |
| Short-term investments | $4.8M | $413.0K | — | — | — | — | — | — | — |
| Receivables | $0 | $229.0K | $901.0K | $720.0K | $488.0K | $10.0M | $965.0K | $523.0K | — |
| Total current assets | $118.7M | $95.0M | $136.4M | $199.1M | $161.8M | $105.6M | $193.7M | $115.7M | — |
| Property, plant and equipment | $1.4M | $3.1M | $6.3M | $11.8M | $25.2M | $35.1M | $39.6M | $21.1M | — |
| Other intangibles | $1.2M | $622.0K | $400.0K | $731.0K | $2.0M | $1.4M | $1.4M | $1.5M | — |
| Total assets | $154.4M | $136.4M | $159.8M | $238.2M | $211.5M | $150.2M | $235.2M | $138.6M | — |
| Accounts payable | $296.0K | $1.3M | $3.0M | $653.0K | $1.1M | $792.0K | $2.0M | $2.2M | — |
| Total current liabilities | $8.9M | $15.0M | $50.0M | $59.7M | $36.0M | $42.8M | $26.9M | $14.1M | — |
| Long-term debt | — | — | — | $22.2M | $2.5M | — | — | — | — |
| Total liabilities | $62.2M | $80.0M | $140.9M | $177.7M | $120.3M | $105.7M | $96.9M | $98.6M | — |
| Retained earnings | -$528.2M | -$482.5M | -$489.6M | -$428.3M | -$316.7M | -$286.1M | -$177.1M | -$85.2M | — |
| Total equity | $92.2M | $56.4M | $18.9M | $60.4M | $91.2M | $44.4M | $138.3M | $40.0M | -$26.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$65.8M | -$58.4M | -$84.1M | -$45.8M | -$10.9M | -$87.4M | -$71.0M | -$51.7M | — |
| Stock-based compensation | $10.2M | $12.6M | $14.0M | $19.2M | $16.5M | $13.8M | $8.9M | $2.5M | — |
| Capital expenditure | $85.0K | $250.0K | $2.0M | $3.3M | $5.1M | $5.0M | $24.7M | $14.3M | — |
| Investing cash flow | -$634.0K | -$215.0K | $5.8M | -$3.3M | -$5.8M | -$5.0M | -$24.7M | -$15.7M | — |
| Financing cash flow | $95.2M | $50.5M | $5.4M | $95.0M | $70.5M | $1.3M | $173.4M | $107.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-013757.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $10.9M | $22.2M | $24.3M | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$46.0M | -$92.9M | -$109.0M | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |